PsO Pipeline Watch: Alumis Inc.’s Oral TYK2 inhibitor, ESK-001, Boasts High Clearance Rates at One Year; Q & A With Dr.Andrew Blauvelt
Alumis Inc.’s investigational oral tyrosine kinase 2 (TYK2) inhibitor, ESK-001, demonstrated a positive clinical response and safety profile after 52 weeks in patients with plaque psoriasis, according to late-breaking Phase 2 data presented at the 2025 American Academy of Dermatology Association (AAD) Annual Meeting in Orlando, FL. In the open-label extension (OLE) STRIDE Trial, patients […]